BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...that product. Taysha adds innovation source through gene therapy fundTaysha Gene Therapies Inc. (NASDAQ:TSHA) and the University of Texas Southwestern Medical Center...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

...studies ribonucleoprotein granules and the role of that type of biomolecular condensate in neurodegenerative diseases; University of Texas Southwestern Medical Center’s Michael...
BioCentury | Dec 2, 2020
Distillery Therapeutics

SQSTM1, INSR identified as targets in sepsis

...Guangzhou Medical University, Guangzhou, Chinaemail: daolin.tang@utsouthwestern.eduCONTACT: Rui Kang, University of Texas Southwestern Medical Center, Dallas, Texasemail: rui.kang@utsouthwestern.edu Claire Quang Third Military Medical University University of Texas Southwestern Medical Center Sequestosome...
BioCentury | Oct 28, 2020
Distillery Therapeutics

STK25 and TAO1 identified as schistosomiasis targets

...al. Science; published online Sept. 25, 2020doi: 10.1126/science.abb7699 CONTACT: James J. Collins III, University of Texas Southwestern Medical Center, Dallas, Texasemail: jamesj.collins@utsouthwestern.edu Claire Quang University of Texas Southwestern Medical Center Serine/threonine...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...for a valuation of $716 million. Former AveXis Inc. executives spun Taysha out of the University of Texas Southwestern Medical Center...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...to raise up to $100 million in a NASDAQ IPO. Founded in partnership with the University of Texas Southwestern Medical Center...
BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

...Investors”). A team of former AveXis Inc. executives spun Taysha Gene Therapies out of the University of Texas Southwestern Medical Center...
...Cytochrome c oxidase assembly factor Danielle Golovin, Staff Writer Zolgensma, onasemnogene abeparvovec-xioi, ScAAV9.CB.SMN (AVXS-101, charisma) AXO-AAV-GM2 Taysha Gene Therapies University of Texas Southwestern Medical Center AveXis...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...University of Massachusetts Medical School and Steven McKnight, chair of the biochemistry department at the University of Texas Southwestern Medical Center...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Academy of Sciences (NAS). Schmid was chair of the Department of Cell Biology at the University of Texas Southwestern Medical Center...
BioCentury | Apr 29, 2020
Emerging Company Profile

Taysha: Applying AAV9 across the CNS

...pipeline of AAV9-based gene therapies for other CNS disorders. The company spun out of the University of Texas Southwestern Medical Center...
...University of Texas Southwestern Medical Center Disease focus: Neurology Clinical status: Preclinical Founded: 2019 by R.A. Session II University collaborators: University of Texas Southwestern Medical Center...
Items per page:
1 - 10 of 394
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...that product. Taysha adds innovation source through gene therapy fundTaysha Gene Therapies Inc. (NASDAQ:TSHA) and the University of Texas Southwestern Medical Center...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

...studies ribonucleoprotein granules and the role of that type of biomolecular condensate in neurodegenerative diseases; University of Texas Southwestern Medical Center’s Michael...
BioCentury | Dec 2, 2020
Distillery Therapeutics

SQSTM1, INSR identified as targets in sepsis

...Guangzhou Medical University, Guangzhou, Chinaemail: daolin.tang@utsouthwestern.eduCONTACT: Rui Kang, University of Texas Southwestern Medical Center, Dallas, Texasemail: rui.kang@utsouthwestern.edu Claire Quang Third Military Medical University University of Texas Southwestern Medical Center Sequestosome...
BioCentury | Oct 28, 2020
Distillery Therapeutics

STK25 and TAO1 identified as schistosomiasis targets

...al. Science; published online Sept. 25, 2020doi: 10.1126/science.abb7699 CONTACT: James J. Collins III, University of Texas Southwestern Medical Center, Dallas, Texasemail: jamesj.collins@utsouthwestern.edu Claire Quang University of Texas Southwestern Medical Center Serine/threonine...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...for a valuation of $716 million. Former AveXis Inc. executives spun Taysha out of the University of Texas Southwestern Medical Center...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...to raise up to $100 million in a NASDAQ IPO. Founded in partnership with the University of Texas Southwestern Medical Center...
BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

...Investors”). A team of former AveXis Inc. executives spun Taysha Gene Therapies out of the University of Texas Southwestern Medical Center...
...Cytochrome c oxidase assembly factor Danielle Golovin, Staff Writer Zolgensma, onasemnogene abeparvovec-xioi, ScAAV9.CB.SMN (AVXS-101, charisma) AXO-AAV-GM2 Taysha Gene Therapies University of Texas Southwestern Medical Center AveXis...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...University of Massachusetts Medical School and Steven McKnight, chair of the biochemistry department at the University of Texas Southwestern Medical Center...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Academy of Sciences (NAS). Schmid was chair of the Department of Cell Biology at the University of Texas Southwestern Medical Center...
BioCentury | Apr 29, 2020
Emerging Company Profile

Taysha: Applying AAV9 across the CNS

...pipeline of AAV9-based gene therapies for other CNS disorders. The company spun out of the University of Texas Southwestern Medical Center...
...University of Texas Southwestern Medical Center Disease focus: Neurology Clinical status: Preclinical Founded: 2019 by R.A. Session II University collaborators: University of Texas Southwestern Medical Center...
Items per page:
1 - 10 of 394